Idelalisib for the treatment of B-cell malignancies

Bibliography

• Vanhaesebroeck B, Stephens L, Hawkins P. PI3K signalling: the path to discovery and understanding. Nat Rev Mol Cell Biol 2012;13(3):195-203
   PubMed Web of Science ®Google Scholar
• Okkenhaug K. Signaling by the phosphoinositide 3-kinase family in immune cells. Annu Rev Immunol 2013;31:675-704
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Welham MJ, Kotani K, et al. P110delta, a novel phosphoinositide 3-kinase in leukocytes. Proc Natl Acad Sci USA 1997;94(9):4330-5
   PubMed Web of Science ®Google Scholar
• Chantry D, Vojtek A, Kashishian A, et al. p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem 1997;272(31):19236-41
   PubMed Web of Science ®Google Scholar
• Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010;116(12):2078-88
   PubMed Web of Science ®Google Scholar
• Meadows SA, Vega F, Kashishian A, et al. PI3Kdelta inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 2012;119(8):1897-900
   PubMed Web of Science ®Google Scholar
• Tzenaki N, Papakonstanti EA. p110delta PI3 kinase pathway: emerging roles in cancer. Front Oncol 2013;3:40
   PubMedGoogle Scholar
• Calvanese V, Fernandez AF, Urdinguio RG, et al. A promoter DNA demethylation landscape of human hematopoietic differentiation. Nucleic Acids Res 2012;40(1):116-31
   PubMed Web of Science ®Google Scholar
• Pauls SD, Lafarge ST, Landego I, et al. The phosphoinositide 3-kinase signaling pathway in normal and malignant B cells: activation mechanisms, regulation and impact on cellular functions. Front Immunol 2012;3:224
   PubMed Web of Science ®Google Scholar
• Kok K, Nock GE, Verrall EA, et al. Regulation of p110delta PI 3-kinase gene expression. PLoS One 2009;4(4):e5145
   Google Scholar
• Whitehead MA, Bombardieri M, Pitzalis C, Vanhaesebroeck B. Isoform-selective induction of human p110delta PI3K expression by TNFalpha: identification of a new and inducible PIK3CD promoter. Biochem J 2012;443(3):857-67
   Google Scholar
• Lucas CL, Kuehn HS, Zhao F, et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency. Nat Immunol 2014;15(1):88-97
   PubMed Web of Science ®Google Scholar
• Angulo I, Vadas O, Garcon F, et al. Phosphoinositide 3-kinase delta gene mutation predisposes to respiratory infection and airway damage. Science 2013;342(6160):866-71
   PubMed Web of Science ®Google Scholar
• Okkenhaug K, Bilancio A, Farjot G, et al. Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 2002;297(5583):1031-4
   PubMed Web of Science ®Google Scholar
• Fruman DA, Rommel C. PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 2014;13(2):140-56
   PubMed Web of Science ®Google Scholar
• Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007;129(7):1261-74
   PubMed Web of Science ®Google Scholar
• Alessi DR, James SR, Downes CP, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 1997;7(4):261-9
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307(5712):1098-101
   PubMed Web of Science ®Google Scholar
• Okkenhaug K, Ali K, Vanhaesebroeck B. Antigen receptor signalling: a distinctive role for the p110delta isoform of PI3K. Trends Immunol 2007;28(2):80-7
   Google Scholar
• Fruman DA, Cantley LC. Idelalisib–a PI3Kdelta inhibitor for B-cell cancers. N Engl J Med 2014;370(11):1061-2
   PubMed Web of Science ®Google Scholar
• Beckwith M, Fenton RG, Katona IM, Longo DL. Phosphatidylinositol-3-kinase activity is required for the anti-ig-mediated growth inhibition of a human B-lymphoma cell line. Blood 1996;87(1):202-10
   Google Scholar
• Herman SE, Johnson AJ. Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia. Clin Cancer Res 2012;18(15):4013-18
   PubMed Web of Science ®Google Scholar
• Rickert RC. New insights into pre-BCR and BCR signalling with relevance to B cell malignancies. Nat Rev Immunol 2013;13(8):578-91
   PubMed Web of Science ®Google Scholar
• Jou ST, Carpino N, Takahashi Y, et al. Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol Cell Biol 2002;22(24):8580-91
   PubMed Web of Science ®Google Scholar
• Bilancio A, Okkenhaug K, Camps M, et al. Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells. Blood 2006;107(2):642-50
   PubMed Web of Science ®Google Scholar
• Clayton E, Bardi G, Bell SE, et al. A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med 2002;196(6):753-63
   PubMed Web of Science ®Google Scholar
• Vanhaesebroeck B, Khwaja A. PI3Kdelta inhibition hits a sensitive spot in B cell malignancies. Cancer Cell 2014;25(3):269-71
   Google Scholar
• Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 1999;94(11):3658-67
   PubMed Web of Science ®Google Scholar
• Rozovski U, Wu JY, Harris DM, et al. Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood 2014;123(24):3797-802
   PubMed Web of Science ®Google Scholar
• Burger JA, Okkenhaug K. Haematological cancer: idelalisib-targeting PI3Kdelta in patients with B-cell malignancies. Nature reviews Clinical oncology 2014;11(4):184-6
   Google Scholar
• Burger JA, Ghia P, Rosenwald A, Caligaris-Cappio F. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009;114(16):3367-75
   PubMed Web of Science ®Google Scholar
• Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 3’-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood 2011;118(13):3603-12
   PubMed Web of Science ®Google Scholar
• Meads MB, Hazlehurst LA, Dalton WS. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 2008;14(9):2519-26
   PubMed Web of Science ®Google Scholar
• Mraz M, Zent CS, Church AK, et al. Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin alpha-4-beta-1 (VLA-4) with natalizumab can overcome this resistance. Br J Haematol 2011;155(1):53-64
   PubMed Web of Science ®Google Scholar
• ten Hacken E, Burger JA. Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia–focus on the B-cell receptor. Clin Cancer Res 2014;20(3):548-56
   Google Scholar
• Sugimoto Y, Whitman M, Cantley LC, Erikson RL. Evidence that the Rous sarcoma virus transforming gene product phosphorylates phosphatidylinositol and diacylglycerol. Proc Natl Acad Sci USA 1984;81(7):2117-21
   PubMed Web of Science ®Google Scholar
• Whitman M, Kaplan DR, Schaffhausen B, et al. Association of phosphatidylinositol kinase activity with polyoma middle-T competent for transformation. Nature 1985;315(6016):239-42
   PubMed Web of Science ®Google Scholar
• Whitman M, Downes CP, Keeler M, et al. Type I phosphatidylinositol kinase makes a novel inositol phospholipid. phosphatidylinositol-3-phosphate. Nature 1988;332(6165):644-6
   Google Scholar
• Carpenter CL, Duckworth BC, Auger KR, et al. Purification and characterization of phosphoinositide 3-kinase from rat liver. J Biol Chem 1990;265(32):19704-11
   PubMed Web of Science ®Google Scholar
• Leevers SJ, Weinkove D, MacDougall LK, et al. The Drosophila phosphoinositide 3-kinase Dp110 promotes cell growth. EMBO J 1996;15(23):6584-94
   PubMed Web of Science ®Google Scholar
• Chang HW, Aoki M, Fruman D, et al. Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase. Science 1997;276(5320):1848-50
   Google Scholar
• Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem 1994;269(7):5241-8
   PubMed Web of Science ®Google Scholar
• Sadhu C, Masinovsky B, Dick K, et al. Essential role of phosphoinositide 3-kinase delta in neutrophil directional movement. J Immunol 2003;170(5):2647-54
   PubMed Web of Science ®Google Scholar
• Brana I, Siu LL. Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment. BMC Med 2012;10:161
   PubMed Web of Science ®Google Scholar
• Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011;117(2):591-4
   PubMed Web of Science ®Google Scholar
• Berndt A, Miller S, Williams O, et al. The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors. Nat Chem Biol 2010;6(2):117-24
   PubMed Web of Science ®Google Scholar
• Ali K, Bilancio A, Thomas M, et al. Essential role for the p110delta phosphoinositide 3-kinase in the allergic response. Nature 2004;431(7011):1007-11
   PubMed Web of Science ®Google Scholar
• Laffargue M, Calvez R, Finan P, et al. Phosphoinositide 3-kinase gamma is an essential amplifier of mast cell function. Immunity 2002;16(3):441-51
   PubMed Web of Science ®Google Scholar
• Jia S, Liu Z, Zhang S, et al. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 2008;454(7205):776-9
   PubMed Web of Science ®Google Scholar
• Guillermet-Guibert J, Bjorklof K, Salpekar A, et al. The p110beta isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110gamma. Proc Natl Acad Sci USA 2008;105(24):8292-7
   PubMed Web of Science ®Google Scholar
• Christian SL, Sims PV, Gold MR. The B cell antigen receptor regulates the transcriptional activator beta-catenin via protein kinase C-mediated inhibition of glycogen synthase kinase-3. J Immunol 2002;169(2):758-69
   Google Scholar
• Healy JI, Dolmetsch RE, Timmerman LA, et al. Different nuclear signals are activated by the B cell receptor during positive versus negative signaling. Immunity 1997;6(4):419-28
   Google Scholar
• Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 2012;120(6):1175-84
   PubMed Web of Science ®Google Scholar
• Ikeda H, Hideshima T, Fulciniti M, et al. PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood 2010;116(9):1460-8
   PubMed Web of Science ®Google Scholar
• Herman SE, Lapalombella R, Gordon AL, et al. The role of phosphatidylinositol 3-kinase-delta in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. Blood 2011;117(16):4323-7
   PubMed Web of Science ®Google Scholar
• Iyengar S, Clear A, Bodor C, et al. P110alpha-mediated constitutive PI3K signaling limits the efficacy of p110delta-selective inhibition in mantle cell lymphoma, particularly with multiple relapse. Blood 2013;121(12):2274-84
   PubMed Web of Science ®Google Scholar
• Yang Q, Chen LS, Neelapu SS, Gandhi V. The PI3Kδ inhibitor, idelalisib, inhibits transcription and translation through PI3K/Akt pathway in mantle cell lymphoma [abstract]. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 5 - 9 April 2014; San Diego, CA
   Google Scholar
• Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014;123(22):3390-7
   PubMed Web of Science ®Google Scholar
• Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014;370(11):997-1007
   PubMed Web of Science ®Google Scholar
• Gopal AK, Kahl BS, de Vos S, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med 2014;370(11):1008-18
   PubMed Web of Science ®Google Scholar
• Flinn IW, Kahl BS, Leonard JP, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood 2014;123(22):3406-13
   PubMed Web of Science ®Google Scholar
• Kahl BS, Spurgeon SE, Furman RR, et al. A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood 2014;123(22):3398-405
   PubMed Web of Science ®Google Scholar
• Patton DT, Garden OA, Pearce WP, et al. Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells. J Immunol 2006;177(10):6598-602
   PubMed Web of Science ®Google Scholar
• Ali K, Soond DR, Pineiro R, et al. Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 2014;510(7505):407-11
   PubMed Web of Science ®Google Scholar
• Liu D, Zhang T, Marshall AJ, et al. The p110delta isoform of phosphatidylinositol 3-kinase controls susceptibility to Leishmania major by regulating expansion and tissue homing of regulatory T cells. J Immunol 2009;183(3):1921-33
   PubMed Web of Science ®Google Scholar
• Jin F, Robeson M, Zhou H, et al. Pharmacokinetics, metabolism and excretion of idelalisib [abstract]. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 5-9 April 2014; abstract 4633
   Google Scholar
• Jin F, Robeson M, Zhou H, et al. Pharmacokinetics and safety of idelalisib, a novel PI3Kδ inhibitor, in Japanese and Caucasian subjects [abstract]. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 5 - 9 April 2014; abstract CT217
   Google Scholar
• O’Brien SM, Lamanna N, Kipps TJ, et al. A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [abstract]. J Clin Oncol 2013;31(Suppl):abstr 7005
   Google Scholar
• Fowler NH, De Vos S, Schreeder MT, et al. Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) inhibitor GS–1101 (CAL-101) with rituximab and/or bendamustine are tolerable and highly active in previously treated, indolent non-hodgkin lymphoma: results from a phase i study [abstract]. 54th ASH Annual Meeting and Exposition; 2012. abstract 3645
   Google Scholar
• Leonard JP, Wagner-Johnston ND, et al. Tolerability and activity of combinations of the PI3Kδ inhibitor idelalisib (GS-1101) with rituximab and/or bendamustine in patients with previously treated, indolent non-Hodgkin lymphoma (iNHL): updated results from a phase I study [abstract]. J Clin Oncol 2013;31(Suppl):abstract 8500
   Google Scholar
• Coutre SE, Byrd JC, Furman RR, et al. Phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3–kinase P110d, in patients with previously treated chronic lymphocytic leukemia [abstract]. J Clin Oncol 2011;29(Suppl):abstract 6631
   Google Scholar
• Coutre SE, Leonard JP, Barrientos JC, et al. Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation [abstract]. 55th ASH Annual Meeting and Exposition 2013. abstract 1632
   Google Scholar
• Spurgeon SE, Wagner-Johnston ND, Furman RR, et al. Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110δ (PI3Kδ), in patients with relapsed or refractory mantle cell lymphoma (MCL) [abstract]. J Clin Oncol 2013;31(Suppl):abstract 8519
   Google Scholar
• Eradat H, Coutre SE, Barrientos JC, et al. A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL) [abstract]. J Clin Oncol 2013;31(Suppl):abstract TPS7133
   Google Scholar
• Leonard JP, Zinzani PL, Jurczak WJ, et al. A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL) [abstract]. J Clin Oncol 2013;31(Suppl):abstract TPS8617
   Google Scholar
• De Vos S, Sehn LH, Mulligan SP, et al. A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL) [abstract]. J Clin Oncol 2013;31(Suppl):abstract TPS8618
   Google Scholar
• Flinn I, Kimby E, Cotter FE, et al. A phase III, randomized, controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL) [abstract]. J Clin Oncol 2013;31(Suppl):abstract TPS7131
   Google Scholar
• Jin F, Robeson M, Zhou H, et al. The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment [abstract]. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 5-9 April 2014; San Diego, CA; 2014. abstract CT204
   Google Scholar
• Jin F, Robeson M, Zhou H, et al. Evaluation Of the effect of idelalisib on the QT/QTc interval in healthy subjects. Blood (ASH Annual Meeting Abstracts) 2013. 122(21):abstract 5573
   Google Scholar
• Shah P, Balakrishnan K, Wierda W, Gandhi V. Mechanism-based combination therapy of PI3 kinase delta-specific inhibitor Idelalisib with Bendamustine in chronic lymphocytic leukemia [abstract]. Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 5-9 April 2014; San Diego, CA; 2014. abstract 4530
   Google Scholar
• Czech MP. PIP2 and PIP3: complex roles at the cell surface. Cell 2000;100(6):603-6
   PubMed Web of Science ®Google Scholar
• Benson DM, Kahl BS, Furman RR, et al. Final results of a phase I study of idelalisib, a selective inhibitor of PI3Kδ, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL) [abstract]. J Clin Oncol 2013;31(Suppl):abstr 8526
   Google Scholar
• Flinn I, Schreeder MT, Coutre SE, et al. A phase I study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3–kinase P110δ, in combination with anti-CD20 monoclonal antibody therapy and/or bendamustine in patients with previously treated B-cell malignancies [abstract]. J Clin Oncol 2011;29(Suppl):abstract 3064
   Google Scholar
• Wagner-Johnston ND, De Vos S, Leonard JP, et al. Preliminary results of PI3Kδ inhibitor idelalisib (GS-1101) treatment in combination with everolimus, bortezomib, or bendamustine/rituximab in patients with previously treated mantle cell lymphoma (MCL) [abstract]. J Clin Oncol 2013;31(Suppl):abstract 8501
   Google Scholar
• Coutre SE, Leonard JP, Furman RR, et al. Combinations of the selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with rituximab and/or bendamustine are tolerable and highly active in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL): results from a phase i study [abstract]. 54 ASH Annual Meeting and Exposition; 8-11th Dec, Atlanta, GA; 2012: (abstract) 2012. abstract 191
   Google Scholar
• Barrientos JC, Furman RR, Leonard JP, et al. Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL [abstract]. J Clin Oncol 2013;31(Suppl):abstract 7017
   Google Scholar
• Sharman JP, de Vos S, Leonard JP, et al. A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3K{delta}) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) [abstract]. Blood (ASH Annual Meeting Abstracts) 2011. 118(21):abstract 1787
   Google Scholar
• Coutre SE, Barrientos JC, Leonard JP, et al. Phase 1b study of idelalisib (GS-1101) plus chlorambucil ± rituximab in patients with relapsed and refractory chronic lymphocytic leukemia (CLL) [abstract]. XV iwCLL; 8-11th, Sep. Cologne, Germany; 2013: abstract 2013
   Google Scholar
• Barrientos JC, Wagner-Johnston ND, De Vos S, et al. Chemo-immunotherapy combination of idelalisib with bendamustine/rituximab or chlorambucil/rituximab in patients with relapsed/refractory cll demonstrates efficacy and tolerability [abstract]. 55th ASH Annual Meeting and Exposition 2013; abstract 4176
   Google Scholar
• De Vos S, Furman RR, Barrientos JC, et al. Idelalisib, a Selective Inhibitor Of PI3Kδ, In Combination With Bendamustine, Fludarabine Or Chlorambucil In Patients With Relapsed Or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) [abstract]. 55th ASH Annual Meeting and Exposition; 7-10 Dec. New Orleans, LA; 2013. abstract 2878
   Google Scholar
• Furman RR, De Vos S, Leonard JP, et al. A Phase 1 study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with therapeutic anti-cd20 antibodies (rituximab or ofatumumab) in patients with relapsed or refractory chronic lymphocytic leukemia [abstract]. 55th ASH Annual Meeting and Exposition; 7-10 Dec. New Orleans, LA; 2013. abstract 4180
   Google Scholar
• Furman RR, Barrientos JC, Sharman JP, et al. A phase I/II study of the selective phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL) [abstract]. J Clin Oncol 2012;30(Suppl):abstract 6518
   Google Scholar
• Younes A, Moskowitz AJ, Moscinski LC. Pilot Phase 2 study of idelalisib, a selective inhibitor of PI3Kd, in patients with heavily pretreated Hodgkin lymphoma (HL). [abstract]. 12th International Conference on Malignant Lymphoma (ICML); 19-22nd,Jun Lugano, Switzerland; 2013. abstract 139
   Google Scholar
• Coutre SE, Furman RR, Sharman JP, et al. Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL. [abstract]. J Clin Oncol 2014;32(Suppl):abstract 7012
   Google Scholar
• Sharman JP, Coutre SE, Furman RR, et al. Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial. [abstract]. J Clin Oncol 2014;32(Suppl):abstract 7011
   Google Scholar